These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 947510

  • 21. Combination chemotherapy in the treatment of advanced breast cancer.
    Rosner D, Nemoto T, Dao TL.
    J Surg Oncol; 1976; 8(6):465-9. PubMed ID: 994508
    [Abstract] [Full Text] [Related]

  • 22. Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study.
    Kolarić K, Vukas D, Potrebica V.
    Tumori; 1989 Apr 30; 75(2):132-6. PubMed ID: 2741218
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer.
    Mouridsen HT, Palshof T, Brahm M, Rahbek I.
    Cancer Treat Rep; 1977 Apr 30; 61(1):47-50. PubMed ID: 324620
    [Abstract] [Full Text] [Related]

  • 24. Adriamycin in combination chemotherapy of adult acute lymphoblastic leukemia: a Southwest Oncology Group study.
    Shaw MT, Raab SO.
    Med Pediatr Oncol; 1977 Apr 30; 3(3):261-6. PubMed ID: 284167
    [Abstract] [Full Text] [Related]

  • 25. cis-platinum-based alternating non-cross-resistant chemotherapy as a first-line treatment in metastatic breast cancer. A phase II study.
    Kolarić K, Tomek R.
    Tumori; 1990 Oct 31; 76(5):472-5. PubMed ID: 2256193
    [Abstract] [Full Text] [Related]

  • 26. Chemotherapy of advanced breast cancer: a randomized trial of vincristine, Adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP).
    Carmo-Pereira J, Costa FO, Henriques E.
    Cancer; 1981 Oct 01; 48(7):1517-21. PubMed ID: 7026020
    [Abstract] [Full Text] [Related]

  • 27. Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study.
    Tranum BL, McDonald B, Thigpen T, Vaughn C, Wilson H, Maloney T, Costanzi J, Bickers J, el Mawli NG, Palmer R, Hoogstraten B, Heilburn L, Rasmusen S.
    Cancer; 1982 Mar 01; 49(5):835-9. PubMed ID: 7037152
    [No Abstract] [Full Text] [Related]

  • 28. Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer.
    Ahmann DL, Bisel HF, Eagan RT, Edmonson JH, Hahn RG.
    Cancer Chemother Rep; 1974 Mar 01; 58(6):877-82. PubMed ID: 4614896
    [No Abstract] [Full Text] [Related]

  • 29. Response and survival in advanced breast cancer after two non-cross-resistant combinations.
    Brambilla C, De Lena M, Rossi A, Valagussa P, Bonadonna G.
    Br Med J; 1976 Apr 03; 1(6013):801-4. PubMed ID: 1260337
    [Abstract] [Full Text] [Related]

  • 30. Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin.
    Merrin C, Etra W, Wajsman Z, Baumgartner G, Murphy G.
    J Urol; 1976 Jan 03; 115(1):86-8. PubMed ID: 1107604
    [Abstract] [Full Text] [Related]

  • 31. CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study.
    Kolarić K, Roth A, Vukas D, Cervek J.
    Cancer Chemother Pharmacol; 1984 Jan 03; 13(2):142-4. PubMed ID: 6380789
    [Abstract] [Full Text] [Related]

  • 32. [Efficacy of doxorubicin (adriamycin) in disseminated forms of breast cancer].
    Trofimova NB, Gorbunova VA.
    Antibiotiki; 1983 Aug 03; 28(8):625-8. PubMed ID: 6638976
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study.
    Tormey DC, Weinberg VE, Leone LA, Glidewell OJ, Perloff M, Kennedy BJ, Cortes E, Silver RT, Weiss RB, Aisner J.
    Am J Clin Oncol; 1984 Jun 03; 7(3):231-9. PubMed ID: 6375344
    [Abstract] [Full Text] [Related]

  • 37. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer.
    Smalley RV, Lefante J, Bartolucci A, Carpenter J, Vogel C, Krauss S.
    Breast Cancer Res Treat; 1983 Jun 03; 3(2):209-20. PubMed ID: 6688538
    [Abstract] [Full Text] [Related]

  • 38. Systemic chemotherapy of advanced head and neck malignancies.
    Dowell KE, Armstrong DM, Aust JB, Cruz AB.
    Cancer; 1975 Apr 03; 35(4):1116-20. PubMed ID: 1116105
    [Abstract] [Full Text] [Related]

  • 39. Adjuvant treatment of cancer. II. Breast carcinoma.
    Viola MV, Nystrom JS.
    Conn Med; 1977 Jun 03; 41(6):333-5. PubMed ID: 872584
    [No Abstract] [Full Text] [Related]

  • 40. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.
    Bull JM, Tormey DC, Li SH, Carbone PP, Falkson G, Blom J, Perlin E, Simon R.
    Cancer; 1978 May 03; 41(5):1649-57. PubMed ID: 348293
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.